Next Article in Journal
Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction
Previous Article in Journal
Mutual Balance between Vasohibin-1 and Soluble VEGFR-1 in Endothelial Cells
Pharmaceuticals 2011, 4(6), 794-803; doi:10.3390/ph4060794

Use of Intravenous Amiodarone in the Treatment of Nifekalant-Resistant Arrhythmia: A Review of 11 Consecutive Cases with Severe Heart Failure

1, 1,* , 1, 1, 1, 1, 1, 1, 1,2, 3, 4, 1,5 and 1
1 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 7008558, Japan 2 Department of Cardiology, National Hospital Organization Iwakuni Medical Center, Iwakuni, 7400304, Japan 3 Department of Cardiology, Okayama Heart Clinic, Okayama, 7008558, Japan 4 Department of Cardiology, Okayama Redcross Hospital, Okayama, 7008558, Japan 5 Department of Cardiology, Cardiovascular Center Sakakibara Hospital, Okayama, 7008558, Japan
* Author to whom correspondence should be addressed.
Received: 25 March 2011 / Revised: 25 May 2011 / Accepted: 27 May 2011 / Published: 31 May 2011
View Full-Text   |   Download PDF [143 KB, uploaded 31 May 2011]   |  


Background: Both nifekalant hydrochloride (NIF), a selective IKr blocker, and intravenous amiodarone (AMD), a multi-channel (including IKr blocking) blocker, have been reported to be efficacious for refractory arrhythmias. However, the optimal use of those antiarrhythmic drugs for refractory arrhythmia with severe heart failure has not been established. Intravenous AMD might be effective for arrhythmias refractory to NIF in patients with severe heart failure. Here, we report that intravenous amiodarone was effective in the treatment of nifekalant-resistant in a group of arrhythmia patients with severe heart failure. Methods: Eleven severe heart failure patients who had received intravenous AMD for treatment of NIF-resistant arrhythmias were included in this study, and retrospective analysis was performed. Clinical efficacy (terminative and preventive effects on arrhythmia) of intravenous AMD was evaluated. Results: All cases were emergent cases and had depressed left ventricular ejection fraction (30 ± 13%). Clinical arrhythmias were ventricular fibrillation (VF) in four patients, ventricular tachycardia (VT) in six patients, and atrial fibrillation (AF) in one patient. NIF was administered to all patients by intravenous injection. After administration of NIF, VT/VF/AF was terminated in seven of the 10 patients, but a preventive effect was not obtained in any of the patients (NIF-resistance). Intravenous AMD (maintenance dose: 484 ± 166 mg/day) was effective both in termination (80%) and in prevention (80%) of VT/VF events in those patients. It was also effective in termination (80%) and prevention (60%) of AF events refractory to NIF. During continuous AMD administration, no significant adverse effects or proarrhythmic effects were observed in any of the patients. Five patients died within one month, but there was no arrhythmic deaths. Conclusions: Intravenous AMD was effective in NIF-resistant lethal arrhythmias and was relatively safe in emergent cases with severe heart failure.
Keywords: arrhythmias; heart failure; ventricular arrhythmia; atrial fibrillation arrhythmias; heart failure; ventricular arrhythmia; atrial fibrillation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Nakagawa, K.; Nakamura, K.; Kusano, K.F.; Nagase, S.; Tada, T.; Murakami, M.; Hata, Y.; Morita, H.; Kohno, K.; Hina, K.; Ujihira, T.; Ohe, T.; Ito, H. Use of Intravenous Amiodarone in the Treatment of Nifekalant-Resistant Arrhythmia: A Review of 11 Consecutive Cases with Severe Heart Failure. Pharmaceuticals 2011, 4, 794-803.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert